celinehh94

5 ms·

1.
by celinehh94 3y ago
I'm the Founder/CEO - appreciate the excitement! :) Lot's of work to do still, but a very important step for dogs and for lifespan extension pharmaceuticals.
2.
Ambition and SSRIs(celinehh.com)
3 points by celinehh94 3y ago|0 comments
3.
by celinehh94 5y ago
Congrats Maddie & team!!!
4.
by celinehh94 5y ago
hey dang, I'm the author. Thanks for cleaning everything up - I'm sometimes a bit nervous when my work gets posted on HN for what happened here. I really appreciate you & the HN team being so proactive in fixing it!
5.
From Academia to Startups – Common Founder Foibles(celinehh.com)
1 points by celinehh94 6y ago|0 comments
6.
by celinehh94 6y ago
Hey! I’m the author. Biotech is not as well comp’ed, especially when you compare years of experience. For context, senior (Director, VP) levels make low to mid 200s, PhDs with work experience make mid 100s, and straight out of grad school m
7.
by celinehh94 6y ago
Hi! I'm Celine - a little embarrassed this is trending because it is very much still a draft - please forgive any typos! I hope this is helpful and always happy to chat biotech startups - just email me - celinehh.com/about
8.
by celinehh94 7y ago
Sorry - should say use the valuation of the drug to determine patient access to it in the US. AKA, ICER could determine that drug 1 is massively un-cost-effective in comparison to drug 2, but you cannot restrict access to drug 1 due to this
9.
by celinehh94 7y ago
Vaccines are actually super unprofitable for Pharma companies, so this isn't a great model to emulate (although I agree with the general metaphor of gene therapy -> vaccines) https://www.nber.org/papers/w9833
10.
by celinehh94 7y ago
Quick interesting note on this front - ICER is a US non-profit, but has basically zero influence in the actual pricing of drugs. It's actually illegal to value drugs this way in the US